BioLife Solutions, Inc.

03/12/2026

Cell and gene therapies demand precision at every step, including material storage and handling.
As therapies move from clinical development to commercial manufacturing, they must reduce performance risk and enable consistent, scalable processes.

In a new short video, we compare traditional cryobags to the CellSeal® CryoCase, our rigid cryogenic storage container. 🆚

The video explores how evolving cryogenic container design may help reduce variability and improve robustness across the cold chain.🛡️

Watch now: https://youtu.be/K6qVf1XfEjQ?si=h0yeBoT8POjn6oAi

🔎 Need more information on the “case for CryoCase”? Visit this web page:
https://www.biolifesolutions.com/handling/cellseal-cryocase/

03/11/2026

Proud to see Aby J. Mathew, PhD, representing BioLife Solutions today at BioProcess International US West with two important sessions: "Biopreservation Best Practices for Cell-Based Products" and as a panelist at "Preparing for Commercialization of Advanced Therapies".

From biopreservation strategy to commercialization readiness, these are the conversations helping shape the future of advanced therapies. 🧪 ❄️

03/11/2026

Join us at Stanford University's Laboratory for Cell and Gene Medicine on Monday, March 23, for a special Lunch & Learn hosted alongside the upcoming ISCT, International Society for Cell & Gene Therapy (ISCT) Cell Therapy Lab Bootcamp.

🔬 Our Chief Technology Officer, Sean Werner, is giving a presentation on how and why decisions made in the research phase determine clinical reality and outcomes. Sean will elaborate on what you should be thinking about in the research phase to make commercial manufacturing and scaling up easier, consistent, and more reliable.

🧪 Are you or your team interested in hands-on cell therapy manufacturing process training in a GMP-compliant lab environment? There is a September session at GA Tech in Atlanta.

Learn more in the video below and here: https://www.isctglobal.org/workforce-development/hands-on-laboratory-bootcamp-for-cell-therapy-biomanufacturing

Video: https://youtu.be/5wsteu4IrdU?si=uAnLogKmSEmTRLQN

03/10/2026

The BioLife European team will be onsite at the Advanced Therapies UK Congress, March 17-18, at ExCel London.

Grab a coffee or bite to eat and come visit Steven Thompson, Andreas Giger, and Jordi Marti Gascon at Stand 77, close to a café/pub and Track 4. We’d like to chat with you about your cryopreservation protocols, storage container selection, and your fill & finish and thawing processes.

Did you know that this event is Europe's largest commercial cell and gene therapy conference and exhibition?!

The topics range from manufacturing, supply chain, logistics, pricing/market access, R&D in cell and gene therapy, gene-edited cell therapy, immunotherapy, and more. Don’t miss out!

Learn more & register: https://www.terrapinn.com/congress/advanced-therapies/index.stm

03/05/2026

The next G-Rex Grant Tour stop is headed west to San Francisco, CA on March 27.

✅ In this third stop, Ma and Sandy Jones will be onsite. Stop by the BioLife table to meet them and learn how they can help you simplify complex biopreservation and cell processing challenges.

🌟 The speaker line-up is stellar with experts presenting from Stanford, multiple University of California locations, Baylor College, Seattle Children’s Hospital, the California Institute for Regenerative Medicine.

We’re honored to support the Emily Whitehead Foundation, ScaleReady, and all G-Rex grant recipients on this year-long tour.

👉 Register today: https://www.scaleready.com/concepts/g-rex-grant-tour-san-francisco-ca/

03/02/2026

If you’re attending the BioProcess International US West Conference in San Diego in one week (March 9-11), let’s connect! 🌴☀️

We’re exhibiting for the first time at stand 420. Amy Ma and Andrew Sabatier will be onsite to discuss ways to scale-up, improve the efficiency of your downstream workflow, and offer unique closed-system and time saving storage container solutions for final fill & finish. 🧪

We’re thrilled that our Executive Vice President & Chief Scientific Officer, Aby J. Mathew, PhD, will be speaking during the following panel sessions:

🎤 March 11, 2:30pm (Speaker): Biopreservation Best Practices for Cell-Based Products

🎤 March 11, 4:15pm (Moderator): Preparing for Commercialization of Advanced Therapies

Check out the agenda: https://informaconnect.com/bpi-west/agenda/1/

02/26/2026

BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations

Fourth quarter 2025 revenue from continuing operations of $24.8 million, up 20% year-over-year.

Full year 2025 revenue of $96.2 million, up 29% year-over-year.

Join the webcast today, February 26, at 4:30pm ET/1:30pm PT here: https://www.biolifesolutions.com/earnings

Or call in: 1-833-630-0431 or 1-412-317-1808 for international callers

Press Release: https://investors.biolifesolutions.com/2026-02-26-BioLife-Solutions-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-from-Continuing-Operations

02/26/2026

What storage container issues are you continually dealing with during your translational and pre-clinical research?

🚩 Since most cryobags and vials were developed originally for blood banking or the pharmaceutical industry, they don’t fit seamlessly into the workflow of most advanced therapies.

🚩 If you are struggling with container fractures, challenging QA inspections, contamination, automation system flexibility, and variable results, then it might be time to leave the legacy containers behind and consider the CellSeal® CryoCase.

🧩 The CryoCase is a rigid, cryogenic storage container that can reduce these frequent issues. If you want to see how the CryoCase can outperform your legacy container, download the carousel below.

https://www.biolifesolutions.com/wp-content/uploads/2026/02/BioLifeSolutions_Alleviate-CGT-Container-Issues-with-the-CryoCase_021126.pdf

02/25/2026

Achieving regulatory success of cell and gene therapies is equally dependent on manufacturing readiness, biopreservation strategies, handling/distribution controls, and operational ability to scale and sustain, in addition to the clinical data that drives headlines. ⚙️

Our latest Insights Blog explores our theory that when therapy developers engage with suppliers as strategic partners early in development, they inherently reduce regulatory risk and improve approval efficiency. ☑️

In working with various cell and gene therapy customers over the years, we’re seeing that late-stage development changes to materials, cryopreservation methods, or manufacturing workflows are difficult to absorb once regulatory filings are in motion.

🚀 Find out what you can do to get ahead:

Discover how early supplier partnerships strengthen CMC strategy, reduce regulatory risk, and support successful cell therapy FDA approval.

02/18/2026

Will you be at the ScaleReady G-Rex Grant Tour stop in Philadelphia tomorrow, February 19?

Stop by the BioLife table to say hello to Andrew Sabatier. Whether you are scaling up from R&D, navigating clinical trials, or optimizing cryopreservation protocols for commercial production, Andrew can help you find a solution and take advantage of our exclusive G-Rex Grant Recipient offers.

🔔 Event details: https://www.scaleready.com/concepts/g-rex-grant-tour-philadelphia-pa/

See you soon in the city that “loves you back”! 💙🧡

02/17/2026

BioLife Solutions to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 26, 2026

https://investors.biolifesolutions.com/2026-02-17-BioLife-Solutions-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Update-on-February-26,-2026

02/13/2026

Drug Discovery News discusses how the UK’s competitive edge in cell and gene therapy (CGT) is shifting from scientific discovery to industrial scale and ex*****on.

As more therapies move toward clinical use and commercial approval, manufacturing scalability, automation, supportive policy, and funding architecture are becoming the decisive factors. 🧪⚙️

BioLife’s Chief Technology Officer, Sean Werner, comments on the necessity of automation in CGT manufacturing and the difference in cost reductions of allogeneic vs autologous therapies.

If these factors align, the UK is positioned to evolve from a research leader into a globally competitive manufacturing and delivery hub for advanced therapies. 📈

💡 Find out how the UK CGT sector is pushing momentum forward: https://www.drugdiscoverynews.com/can-manufacturing-turn-uk-cell-and-gene-therapy-strength-into-scale-16981